Sanofi survey reveals diabetes misconceptions and screening gaps
Widespread misconceptions about Type 1 diabetes could be contributing to a reluctance to get screened for the autoimmune disease,…
Sanofi reprimanded for disparaging Pfizer’s RSV vaccine
A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging…
New CEO Garijo sketches out vision to redirect Sanofi’s fortunes
In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s…
Sanofi asked to change Dupixent ads after Galderma challenge
Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change…
Sanofi to lay off 229 Blueprint Medicines staffers, close Cambridge offices following acquisition
In the first major workforce reduction disclosed under new CEO Belén Garijo, Sanofi is laying off 229 employees…
EC begins antitrust probe into Sanofi’s flu shot campaign
Nine months after raiding the offices of Sanofi in an unannounced inspection, the European Commission says it has started…
Sanofi unit in Ireland dinged by FDA on Altuviiio production
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the…
Sanofi offers commitments to end EU flu shot antitrust probe
On the heels of a European Commission probe into whether Sanofi “disparaged” one of its flu vaccine rivals…
After FDA delay, Sanofi scores subcutaneous OBI nod for Sarclisa
Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential…
Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas
As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi…
Sanofi announces limited changes to its revamped executive team
With former Merck KGaA CEO Belén Garijo, M.D., Ph.D., now calling the shots at Sanofi, the French drugmaker…
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas
With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives…